avelumab

Home
Ligands
avelumab

GtoPdb Ligand ID: 8735

Synonyms: Bavencio® | MSB-0010718C | MSB0010718C

avelumab is an approved drug (EMA & FDA (2017))

Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

References
1. Nastri HG, Iffland C, Leger O, An Q, Cartwright M, Mckenna SD, Sood VD, Hao G. (2013) Anti-pd-l1 antibodies and uses thereof. Patent number: WO2013079174 A1. Assignee: Merck Patent Gmbh. Priority date: 28/11/2011. Publication date: 06/06/2013.
2. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12 (4): 252-64. [PMID:22437870]
3. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 27 (4): 450-61. [PMID:25858804]

References

1. Nastri HG, Iffland C, Leger O, An Q, Cartwright M, Mckenna SD, Sood VD, Hao G. (2013)
Anti-pd-l1 antibodies and uses thereof.
Patent number: WO2013079174 A1. Assignee: Merck Patent Gmbh. Priority date: 28/11/2011. Publication date: 06/06/2013.

2. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer, 12 (4): 252-64. [PMID:22437870]

3. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell, 27 (4): 450-61. [PMID:25858804]